Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate arid severe ulcerative colitis

Italian Journal of Gastroenterology and Hepatology

Volumn 30, Issue 1, 1998, Pages 62-70

  Renzi, D ^a   Mantellini, P ^a   Calabro A ^a   Panerai, C ^a   Amorosi, A ^a   Salvador, G ^a   Garcea, M R ^a   Surrenti, C ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Inflammation; Neuropeptides; Radioimmunoassay; Ulcerative colitis

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; NEUROPEPTIDE; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ENDOSCOPIC BIOPSY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RADIOIMMUNOASSAY; TISSUE LEVEL; ULCERATIVE COLITIS;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; CALCITONIN GENE-RELATED PEPTIDE; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; RECTUM; SEVERITY OF ILLNESS INDEX; SUBSTANCE P; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0031897473     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:928-37.
2. Shanahan F. Pathogenesis of ulcerative colitis. Lancet 1993; 342:407-11.
3. Shanahan F, Targan SR. Mechanisms of tissue injury in inflammatory bowel disease. In: Targan SR, Shanahan F, editors. Inflammatory bowel disease: from bench to bedside. Baltimore: William & Wilkins, 1994:78-88.
4. Umeda Y, Takamiya M, Yoshizaki H, Arisawa M. Inhibition of mitogen-stimulated T lymphocytes proliferation by calcitonin gene-related peptide. Biochem Biophys Res Commun 1988:154:227-35.
5. McGillis JP, Mitsuhashi M, Payan DG. Immunomodulation by tachykinin neuropeptides. Ann NY Acad Sei 1990:594:85-94.
6. Sirinek LP, O'Dorisio MS. Modulation of immune function by intestinal neuropeptides. Acta Oncol 1991:30:509-17.
7. Fais S, Annibale B, Boirivant M, Santoro A, Pallone F, Delle Fave G. Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation. J Neuroimmunol 1991:31:211-9.
8. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996;! 11:1683-99.
9. Costa M, Furness JB, Llewellyn-Smith IJ. Histochemistry of the enteric nervous system. In: Johnson LR, editor. Physiology of the gastrointestinal tract, 2nd edition. New York: Raven Press, 1987; 1-40.
10. O'Dorisio MS, O'Dorisio TM, Cataland S, Balcerzak SP. VIP as a biochemical marker for polymorphonuclear leukocytes. J Lab Clin Med 1980;96:666-72.
11. Aliakbari J, Sreedharan SP, Turck CW, Goetzl FJ. Selective localization of vasoactive intestinal peptide and substance P in human eosinophils. Biochem Biophys Res Commun 1987;148:1440-5.
12. Cutz E, Chan \V, Track N, Goth H, Said S. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature 1978:275:661-2.
13. Gomariz RP, De la Fuente M, Hernanz A, Leceta J. Occurrence of vasoactive intestinal peptide (VIP) in lymphoid organs from rat and mouse. Ann N Y Acad Sei 1992;650:13-8.
14. Calvo JR, Guerrero JM, Molinero P, Blasco R, Goberna R. Interaction of vasoactive intestinal peplide (VIP) with human peripheral blood lymphocytes: Specific binding and cyclic AMP production. Gen Pharmacol 1986; 17:185-9.
15. Ottaway CA. Role of the neuroendocrine system in cytokine pathways in inflammatory bowel disease. Aliment Pharmacol Ther 1996;10 (Suppl. 2):10-5.
16. Ottaway CA, Greenberg GR. Interaction of VIP with mouse lymphocytes: specific binding and the modulation of mitogen responses. J Immunol 1984; 132:417-23.
17. Stanisz AM, Befus D, Bienenstock J. Differential effects of vasoactive intestinal polypeptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's Patches, mesenteric lymph nodes, and spleen. J Immunol 1986; 136:152-6.
18. Ottaway CA, Husband AJ. The influence of neuroendocrine pathways on lymphocyte migration. Immunology Today 1994; 15:511 -7.
19. Ganea D, Sun L. Vasoactive intestinal peptide downregulates the expression of IL-2 but not of IFNy from stimulated murine T lymphocytes. J Neuroimmunol 1993;47:147-58.
20. Boirivant M, Fais S, Annibale B, Agostini D, Delle Fave G, Pallone F. Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin A production by intestinal lamina propria lymphocytes. Gastroenterology 1994; 106:576-82.
21. Annibale B, Fais S, Boirivant M, Delle Fave G, Pallone F. Effects of high in vivo levels of vasoactive intestinal polypeptide on function of circulating lymphocytes in humans. Gastroenterology 1990;98:1693-8.
22. De la Fuente M, Delgado M, del Rio M, Martinez C, Hernanz A, Gomariz RP. Stimulation by vasoactive intestinal peptide (VIP) of phagocytic function in rat macrophages. Protein Kinase C involvement. Regul Peptides 1993;48:345-53.
23. Sun L, Ganea D. Vasoactive intestinal peptide inhibits IL2 and IL4 production through different molecular mechanisms in T cells activated via TcR/CD3 complex. J Neuroimmunol !993;48:59-69.
24. Martinez C, Delgado M, Gomariz R, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide (PACAP-38) inhibit IL-10 production in murine T lymphocytes. J Immunol 1996; 156:4128-36.
25. VVeinstock JV. Production of neuropeptides by inflammatory cells within the granulomas of murine Schistosomiasis mansoni. Eur J Clin Invest 1991;21:145-53.
26. Costa M, Fumess JB, Llewellyn-Smith IJ. Functional roles for substance P-containing neurones in the gastrointestinal tract. In: Jordan CC, editor. Substance P: metabolism and biological actions. London: Taylor & Frances, 1985:99-119.
27. Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T lymphocytes by substance P. J Immunol 1983;131:1613-5.
28. Shanahan F, Denburg JA, Fox J, Bienenstock J, Befus D. Mast cell heterogeneity: Effect of neuroenteric peptides on histamine release. J Immunol 1985;135:1331-7.
29. Wiedermann CJ, Wiedermann FJ, Apperl A, Kieselbach G, Konwalinka G, Braunsteiner H. In vitro human polymorphonuclear chemokinesis and human monocyte chemotaxis are différent activities of amino terminal and carboxyterminal substance P. Naunyn-Schmiedeberg's Arch Pharmacol 1989; 340:185-90.
30. Wiedermann FJ, Kahler CM, Reinisch N, Wiedermann CJ. Induction of normal human eosinophil migration in vitro by substance P. Acta Haematol 1993 ;89:213-5.
31. Ruff MR, Wahl SM, Pert CB. Substance P receptor-mediated chemotaxis of human monocytes. Peptides 1985;6(Suppl 2): 107-11.
32. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988;241:1218-2I.
33. Calvo CF, Chavenal G, Senik A. Substance P enhances IL2 expression in activated human T-cells. J Immunol 1992; 148:3498-506.
34. Crowe R, Kamm MA, Bumstock G, Lennard-Jones JE. Peptidecontaining neurons in different regions of the submucous plexus of human sigmoid colon. Gastroenterology 1992; 102:461-7.
35. Forster CA, Mandak B, Kromer E, Rot A. Calcitonin gene-related peptide is chemotactic for human T lymphocytes. Ann NY Acad Sei 1992;657:397-404.
36. Nong YH, Titus RG, Ribeiro JM, Remold HG. Peptides encoded by calcitonin gene inhibit macrophage function. J Immunol 19S9;143:45-9.
37. Casini A, Geppetti P, Maggi CA, Surrenti C. Effects of calcitonin gene-related peptide (CGRP), neurokinin A and neurokinin A(410) on the mitogenic response of human peripheral blood mononuclear cells. Naunyn-Schmiedeberg's Arch Pharmacol 1989;339:354-8.
38. Buckley TL, Brain SD, Rampart M, Williams TJ. Time-dependent synergistic interactions between the vasodilator neuropeptide, calcitonin gene-related peptide (CGRP) and mediators of inflammation. Br J Pharmacol 1991;103:1515-9.
39. Holzer P. Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin generelated peptide and other neuropeptides. Neuroscience 1988;24:739-68.
40. Storsteen KA, Kemohan JW, Bargen JA. The myenteric plexus in chronic ulcerative colitis. Surg Gynecol Obstet 1953;97:335-43.
41. Bishop AE, Polak JM, Bryant MG, Bloom SR, Hamilton S. Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease. Gastroenterology 1980;79:853-60.
42. Sjolund R, Schaffalitzky de Muckadell OB, Fahrenkrug J, Hakanson R, Peterson BG, Sundler F. Peptide-containing nerve fibers in the gut wall in Crohn's disease. Gut 1983:24:724-33.
43. O'Morain C, Bishop AE, McGregor GP, Levi AJ, Bloom SR, Polak JM, et al. Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. Gut 1984;25:57-61.
44. Koch TR, Aidan Carney J, Go VLW. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Die Dis Sei 1987:32:369-76.
45. Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in thé colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol 1992;87:176-81.
46. Kubota Y, Petras RE, Ottaway CA, Tubbs RR, Farmer RG, Fiocchi C. Colonie vasoactive intestinal peptide nerves in inflammatory bowel disease. Gastroenterology 1992:102:1242-51.
47. Kimura M, Masuda T, Hiwatashi N, Toyota T, Nagura H. Changes in neuropeptide-containing nerves in human colonie mucosa with inflammatory bowel disease. Pathol Int 1994;44:624-34.
48. Goldin E, Karmeli F, Selinger Z, Rachmilewitz D. Colonie substance P are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sei 1989;34:754-7.
49. Eysselein VE, Reinshagen M, Patel A, Davis W, Nast C, Sternini C. Calcitonin gene-related peptide in inflammatory bowel disease and experimentally induced colitis. Ann NY Acad Sei 1992:657:319-27.
50. Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993:88:908-13.
51. Yamamoto H, Morise K, Kusugami K, Furusawa A, KonagayaT, Nishio Y, et al. Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease. J Gastroenterol 1996:31:525-32.
52. Eysselein VE, Reinshagen M, Cominelli F, Sternini C, Davis W, Patel A, et a!. Calcitonin gene-related peptide and substance P decrease in the rabbit colon during colitis. Gastroenterology 1991:101:1211-9.
53. Miampamba M, Chéry-Croze S, Chayvialle JA. Spinal and intestinal levels of substance P, Calcitonin gene-related peptide and vasoactive intestinal polypeptide following perendoscopic injection of formalin in rat colonie wall. Neuropeptides 1992:22:73-80.
54. Duffy LC, Zielezny MA, Riepenhoff-Talty M, Byers TE, Marshall J, Weiser MM, et al. Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease. Dig Dis Sei 1989:34:1528-35.
55. Rachmilewitz D. Coated mesalazine (5-aminosaIicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 1989:298:82-6.
56. Geppetti P, Frilli S, Renzi D, Santicioli P, Maggi C.A, Theodorsson E, et al. Distribution of Calcitonin gene-related peptide immunoreactivity in various rat tissues: correlation with substance P and other tachykinins and sensitivity to capsaicin. Regul Pept 1988:23:289-98.
57. Renzi D, Mantellini P, Maggi CA, Fucini C, Surrenti C. Ruthenium red selectively antagonizes capsaicin-induced release of vasoactive intestinal polypeptide (VIP) from the human colon. NeurosciLett 1991:126:134-6.
58. Kirk RE. Multiple comparison tests. In: Laughton CD, editor. Experimental design: procedures for the behavioral sciences. Belmom: Brooks/Cole, 1982:112-4.
59. Nielsen OH, Rask-Madsen J. Mediators of inflammation in chronic inflammatory bowel disease. Scand J Gastroenterol 1996:216 (Suppl): 149-59.
60. Metwali A, Blum AM, Ferraris L, Klein JS, Fiocchi C, Weinstock JV. Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol 1994:52:69-78.
61. Tissot M, Pradelles P, Giroud JP. Substance P levels in inflammatory exudates. Inflammation 1988:12:25-5.
62. Ollerenshaw S, Jarvis D, Woolcock A, Sullivan C, Scheibner T. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lunes of patients with asthma. N Engl J Med 1989:320:1244-8.
63. Sirianni MC, Annibale B, Tagliafeni F, Fais S, DeLuca S, Pallone F, et al. Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity. Regul Peptides 1992;38:79-87.
64. McCabe RC, Dharmsathaphom K. Mechanism of VIP-stimulated chloride secretion by intestinal epithelial cells. Ann NY Acad Sei 1987;527:326-45.
65. Ganz P, Sandrock AW, Landis SC, Leopold J Jr, Gimbrone A, Alexander RW. Vasoactive intestinal peptide: vasodilation and cyclic AMP generation. Am J Physiol 1986;250:H755-60.
66. McFadden D, Zinner MJ, Jaffe BM. Substance P-induced intestinal secretion of water and electrolytes. Gut 1986;27:267-72.
67. Kahler CM. Sitte BA, Reinisch N, Wiedermann CJ. Stimulation of chemotactic migration of human fibroblasts by substance P. Eur J Pharmacol 1993:249:281-6.